We believe that our lead product candidates have demonstrated, in clinical trials and/or in relevant preclinical models, potential advantages such as substantial increases in potency, duration of action and/or selectivity relative to existing medicines or potential medicines in late-stage clinical studies.
We have clinical development programs in:


Theravance Clinical Pipeline   

PROGRAMS DEVELOPMENT   Status
Phase 1Phase 2Phase 3NDAApproval
BACTERIAL INFECTIONS            
Telavancin: cSSSI 0 0 0 0    
Telavancin: HAP 0 0 0      
TD-1792 0 0        
RESPIRATORY            
Horizon 0 0        
MABA 0 0        
LAMA 0          
GASTROINTESTINAL MOTILITY            
GI Motility Dysfunction 0 0        
             

0 Proof of Concept     0 Pre-Proof of Concept

In the table above:
  • Phase 1 indicates initial clinical safety testing in healthy volunteers, or studies directed toward understanding the mechanisms of action of the drug.
  • Phase 2 indicates further clinical safety testing and preliminary efficacy testing in a limited patient population.
  • Phase 3 indicates evaluation of clinical efficacy and safety within an expanded patient population.
  • NDA indicates that a new drug application has been submitted to and accepted for filing by the U.S. Food and Drug Administration (FDA).
  • We consider programs in which at least one compound has successfully completed a Phase 2a study showing efficacy and tolerability as having achieved Proof of Concept.
  • "Development Status" indicates the most advanced stage of development that has been completed or is in process.
©2008 Theravance, Inc. Theravance, the Theravance logo and Medicines That Make a Difference are registered trademarks of Theravance, Inc. Trademarks, trade names or service marks of other companies appearing on this website are the property of their respective owners. All rights reserved.

Terms of Use     Website Admin Contact     Theravance Contact     Site Map